pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 16·1 min read
save

Podcast interview challenges the scientific basis of blue zones after 25 years of hype

May 16, 2026·read at STAT ↗Neutral

In a recent First Opinion podcast, Eric Topol and Shelley Wood discuss the rise of the blue zone concept over the past quarter century. They note that the idea began with isolated communities said to enjoy unusually long lives and has since become a staple of the longevity movement.

The hosts question whether the original observations hold up to modern scientific scrutiny, pointing out that many of the longevity claims lack robust controlled data. They argue that the popular narrative may oversimplify complex genetic, environmental, and lifestyle factors.

Ultimately, the conversation underscores that while blue zones have inspired interest in healthy aging, the field needs more rigorous evidence before these regions can serve as definitive models for longevity strategies.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The cloudy truth about ‘blue zones’”

read at STAT ↗
5,316 words · retrieved May 16
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH2Boundless Bio, Inc.
drugs
MIFEPRISTONEOXYGEN
topics
Cardiology5Immunology4Peptide Therapeutic

related stories

  • 4d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Oct 5Could we one day vaccinate against every cancer?STAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: Soufflé cooks up $135M; Matchpoint makes $150MFierce Biotech
  • Sep 145 drugmakers chasing Merck and Moderna in the cancer vaccine raceBioSpace